Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice

View More View Less
  • 1 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

✓ Targeted protein toxins are a new class of reagents with the potential for great tumor selectivity and cytotoxic potency. Two such compounds were studied: 1) Tf-CRM107, a conjugate of human transferrin (Tf) and diphtheria toxin with a point mutation (CRM107); and 2) 454A12-rRA, a conjugate of a monoclonal antibody (454A12) to the human Tf receptor and recombinant ricin A chain (rRA). Both compounds are potent and specific in killing human glioblastoma cell lines in vitro. The authors investigated the activity of these reagents administered intratumorally against solid U251 MG human gliomas in vivo.

Nude mice with established U251 MG flank tumors (0.5 to 1.0 cm in diameter) were randomly assigned to be treated with 100-µl intratumoral injections of Tf-CRM107 (10 µg) or 454A12-rRA (10 µg), equimolar doses of CRM107 (4.3 µg), 454A12 antibody (7.5 µg), or rRA (1.5 µg), or phosphate-buffered saline (PBS) every 2 days for a total of four doses. Tumor volume and animal weight were assessed by a blinded observer before each treatment and biweekly for 30 days after initiating therapy. With Tf-CRM107 administration, tumor regression of greater than 95% occurred by Day 14 (p < 0.01) and tumors did not recur by Day 30. Treatment with 454A12-rRA caused a 30% decrease in tumor volume by Day 14 (p < 0.01). Treatment with equimolar doses of the unconjugated targeted protein toxin components CRM107, 454A12, or rRA caused significant U251 MG tumor growth inhibition, but the effects were less potent than the antitumor effects of the conjugates.

This study also characterized the dose-response effect of Tf-CRM107 on tumor growth and tumor weight on Day 30. Nude mice with established U251 MG flank tumors (0.5 to 1.0 cm in diameter) were treated with 100-µl intratumoral injections of 10, 1.0, or 0.1 µg of Tf-CRM107 or PBS every 2 days for a total of four doses. All three doses of Tf-CRM107 significantly inhibited tumor growth by Day 14 (p < 0.01) and at Day 30 (p < 0.05), with a significant dose-response relationship.

This study demonstrated in vivo efficacy of the targeted toxins Tf-CRM107 and 454A12-rRA against a human glioma. With intratumoral administration, the effect of Tf-CRM107 was tumor-specific and in some animals curative. Regional therapy with these potent tumor-specific agents using direct intratumoral infusion should limit systemic toxicity and may be efficacious against brain tumors.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address reprint requests to: Douglas W. Laske, M.D., Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Building 10, Room 5D-37, 9000 Rockville Pike, Bethesda, Maryland 20892.
  • 1.

    Ammirati M, , Galicich JH, & Arbit E, et al: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607614, 1987 Ammirati M, Galicich JH, Arbit E, et al: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607–614, 1987

    • Search Google Scholar
    • Export Citation
  • 2.

    Angelova-Gateva P: Iron transferrin receptors in rat and human cerebrum. Agressologie 21:2730, 1980 Angelova-Gateva P: Iron transferrin receptors in rat and human cerebrum. Agressologie 21:27–30, 1980

    • Search Google Scholar
    • Export Citation
  • 3.

    Blasberg RG, & Groothuis DR: Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 13:7082, 1986 Blasberg RG, Groothuis DR: Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 13:70–82, 1986

    • Search Google Scholar
    • Export Citation
  • 4.

    Blasberg RG, , Nakagawa H, & Bourdon MA, et al: Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. Cancer Res 47:44324443, 1987 Blasberg RG, Nakagawa H, Bourdon MA, et al: Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. Cancer Res 47:4432–4443, 1987

    • Search Google Scholar
    • Export Citation
  • 5.

    Bosch DA, , Hindmarsch T, & Larsson S, et al: Intraneoplastic administration of bleomycin in intracerebral gliomas: a pilot study. Acta Neurochir Suppl 30:441444, 1980 Bosch DA, Hindmarsch T, Larsson S, et al: Intraneoplastic administration of bleomycin in intracerebral gliomas: a pilot study. Acta Neurochir Suppl 30:441–444, 1980

    • Search Google Scholar
    • Export Citation
  • 6.

    Bouvier G, , Penn RD, & Kroin JS, et al: Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 20:286291, 1987 Bouvier G, Penn RD, Kroin JS, et al: Direct delivery of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 20:286–291, 1987

    • Search Google Scholar
    • Export Citation
  • 7.

    Brem H, , Mahaley MS Jr, & Vick NA, et al: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74:441446, 1991 Brem H, Mahaley MS Jr, Vick NA, et al: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74:441–446, 1991

    • Search Google Scholar
    • Export Citation
  • 8.

    Bullard DE, , Schold SC Jr, & Bigner SH, et al: Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40:410427, 1981 Bullard DE, Schold SC Jr, Bigner SH, et al: Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40:410–427, 1981

    • Search Google Scholar
    • Export Citation
  • 9.

    Connor JR, & Fine RE: The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res 368:319328, 1986 Connor JR, Fine RE: The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res 368:319–328, 1986

    • Search Google Scholar
    • Export Citation
  • 10.

    Faulk WP, , Hsi BL, & Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2:390392, 1980 Faulk WP, Hsi BL, Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2:390–392, 1980

    • Search Google Scholar
    • Export Citation
  • 11.

    FitzGerald D, & Pastan I: Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 81:14551463, 1989 FitzGerald D, Pastan I: Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst 81:1455–1463, 1989

    • Search Google Scholar
    • Export Citation
  • 12.

    Frankel A, , Ring D, & Bjorn M, et al: Breast cancer immunotoxins, in Ceriani R (ed): Monoclonal Antibodies and Breast Cancer: Proceedings of the International Workshop on Monoclonal Antibodies and Breast Cancer. Boston: Martinus Nijhoff, 1985, pp 269292 Frankel A, Ring D, Bjorn M, et al: Breast cancer immunotoxins, in Ceriani R (ed): Monoclonal Antibodies and Breast Cancer: Proceedings of the International Workshop on Monoclonal Antibodies and Breast Cancer. Boston: Martinus Nijhoff, 1985, pp 269–292

    • Search Google Scholar
    • Export Citation
  • 13.

    Galbraith GMP, , Galbraith RM, & Faulk WP: Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunol 49:215222, 1980 Galbraith GMP, Galbraith RM, Faulk WP: Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunol 49:215–222, 1980

    • Search Google Scholar
    • Export Citation
  • 14.

    Garfield J, & Dayan AD: Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate. J Neurosurg 39:315322, 1973 Garfield J, Dayan AD: Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate. J Neurosurg 39:315–322, 1973

    • Search Google Scholar
    • Export Citation
  • 15.

    Garfield J, , Dayan AD, & Weller RO: Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin Oncol 1:213222, 1975 Garfield J, Dayan AD, Weller RO: Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin Oncol 1:213–222, 1975

    • Search Google Scholar
    • Export Citation
  • 16.

    Gatter KC, , Brown G, & Trowbridge IS, et al: Transferrin receptors in human tissue: their distribution and possible clinical relevance. J Clin Pathol 36:539545, 1983 Gatter KC, Brown G, Trowbridge IS, et al: Transferrin receptors in human tissue: their distribution and possible clinical relevance. J Clin Pathol 36:539–545, 1983

    • Search Google Scholar
    • Export Citation
  • 17.

    Geran R, , Greenberg N, & MacDonald M, et al: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3(2): 1103, 1972 Geran R, Greenberg N, MacDonald M, et al: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3(2):1–103, 1972

    • Search Google Scholar
    • Export Citation
  • 18.

    Gilliland DG, , Steplewski Z, & Collier R, et al: Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 77:4539543, 1980 Gilliland DG, Steplewski Z, Collier R, et al: Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 77:4539–543, 1980

    • Search Google Scholar
    • Export Citation
  • 19.

    Gould BJ, , Borowitz MJ, & Groves ES, et al: Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 81:775781, 1989 Gould BJ, Borowitz MJ, Groves ES, et al: Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 81:775–781, 1989

    • Search Google Scholar
    • Export Citation
  • 20.

    Greenfield L, , Johnson VG, & Youle RJ: Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238:536539, 1987 Greenfield L, Johnson VG, Youle RJ: Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238:536–539, 1987

    • Search Google Scholar
    • Export Citation
  • 21.

    Gregg EO, , Bridges SH, & Youle RJ, et al: Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia. J Immunol 138:45024508, 1987 Gregg EO, Bridges SH, Youle RJ, et al: Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia. J Immunol 138:4502–4508, 1987

    • Search Google Scholar
    • Export Citation
  • 22.

    Griffin TW, , Richardson C, & Houston LL, et al: Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Cancer Res 47:42664270, 1987 Griffin TW, Richardson C, Houston LL, et al: Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Cancer Res 47:4266–4270, 1987

    • Search Google Scholar
    • Export Citation
  • 23.

    Hill JM, , Ruff MR, & Weber RJ, et al: Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 82:45534557, 1985 Hill JM, Ruff MR, Weber RJ, et al: Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sci USA 82:4553–4557, 1985

    • Search Google Scholar
    • Export Citation
  • 24.

    Hochberg FH, & Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907911, 1980 Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911, 1980

    • Search Google Scholar
    • Export Citation
  • 25.

    Jain RK: Delivery of novel therapeutic agents in tumors: physiological barrier and strategies. J Natl Cancer Inst 81:570576, 1989 Jain RK: Delivery of novel therapeutic agents in tumors: physiological barrier and strategies. J Natl Cancer Inst 81:570–576, 1989

    • Search Google Scholar
    • Export Citation
  • 26.

    Jansen FK, , Blythman HE, & Carrière D, et al: Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62:185216, 1982 Jansen FK, Blythman HE, Carrière D, et al: Immunotoxins: hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62:185–216, 1982

    • Search Google Scholar
    • Export Citation
  • 27.

    Jeffries WA, , Brandon MR, & Hunt SV, et al: Transferrin receptor on endothelium of brain capillaries. Nature 312:162163, 1984 (Letter) Jeffries WA, Brandon MR, Hunt SV, et al: Transferrin receptor on endothelium of brain capillaries. Nature 312:162–163, 1984 (Letter)

    • Search Google Scholar
    • Export Citation
  • 28.

    Johnson VG, , Wrobel C, & Wilson D, et al: Improved tumorspecific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 70:240248, 1989 Johnson VG, Wrobel C, Wilson D, et al: Improved tumorspecific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 70:240–248, 1989

    • Search Google Scholar
    • Export Citation
  • 29.

    Kanellos J, , McKenzie IF, & Pietersz GA: Intratumor therapy of solid tumors with ricin-antibody conjugates. Immunol Cell Biol 67:8999, 1989 Kanellos J, McKenzie IF, Pietersz GA: Intratumor therapy of solid tumors with ricin-antibody conjugates. Immunol Cell Biol 67:89–99, 1989

    • Search Google Scholar
    • Export Citation
  • 30.

    Kroin JS, & Penn RD: Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 10:349354, 1982 Kroin JS, Penn RD: Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery 10:349–354, 1982

    • Search Google Scholar
    • Export Citation
  • 31.

    Krolick KA, , Uhr JW, & Slavin S, et al: In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins. J Exp Med 155:797809, 1982 Krolick KA, Uhr JW, Slavin S, et al: In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins. J Exp Med 155:797–809, 1982

    • Search Google Scholar
    • Export Citation
  • 32.

    Larrick JW, & Cresswell P: Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct 11:579586, 1979 Larrick JW, Cresswell P: Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct 11:579–586, 1979

    • Search Google Scholar
    • Export Citation
  • 33.

    Lashford LS, , Davies AG, & Richardson RB, et al: Apilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 61:857868, 1988 Lashford LS, Davies AG, Richardson RB, et al: Apilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 61:857–868, 1988

    • Search Google Scholar
    • Export Citation
  • 34.

    Levin VA, , Freeman-Dove M, & Landahl HD: Permeability characteristics of brain adjacent to tumors in rats. Arch Neurol 32:785791, 1975 Levin VA, Freeman-Dove M, Landahl HD: Permeability characteristics of brain adjacent to tumors in rats. Arch Neurol 32:785–791, 1975

    • Search Google Scholar
    • Export Citation
  • 35.

    Morantz RA, , Kimler BF, & Vats TS, et al: Bleomycin and brain tumors. A review. J Neurooncol 1:249255, 1983 Morantz RA, Kimler BF, Vats TS, et al: Bleomycin and brain tumors. A review. J Neurooncol 1:249–255, 1983

    • Search Google Scholar
    • Export Citation
  • 36.

    Morrison PF, & Dedrick RL: Transport of cisplatin in rat brain following microinfusion: an analysis. J Pharm Sci 75:120128, 1986 Morrison PF, Dedrick RL: Transport of cisplatin in rat brain following microinfusion: an analysis. J Pharm Sci 75:120–128, 1986

    • Search Google Scholar
    • Export Citation
  • 37.

    Neville DM Jr, , Scharff J, & Srinivasachar K: In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 89:25852589, 1992 Neville DM Jr, Scharff J, Srinivasachar K: In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 89:2585–2589, 1992

    • Search Google Scholar
    • Export Citation
  • 38.

    Nierenberg D, , Harbaugh R, & Maurer LH, et al: Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. Neurosurgery 28:752761, 1991 Nierenberg D, Harbaugh R, Maurer LH, et al: Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. Neurosurgery 28:752–761, 1991

    • Search Google Scholar
    • Export Citation
  • 39.

    Patchell RA, , Tibbs PA, & Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494500, 1990 Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500, 1990

    • Search Google Scholar
    • Export Citation
  • 40.

    Penn RD, , Kroin JS, & Harris JE, et al: Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil. Appl Neurophysiol 46:240244, 1983 Penn RD, Kroin JS, Harris JE, et al: Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil. Appl Neurophysiol 46:240–244, 1983

    • Search Google Scholar
    • Export Citation
  • 41.

    Prior R, , Reifenberger G, & Wechsler W: Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 416:491496, 1990 Prior R, Reifenberger G, Wechsler W: Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction. Virchows Arch A Pathol Anat Histopathol 416:491–496, 1990

    • Search Google Scholar
    • Export Citation
  • 42.

    Rall DF, & Zubrod CG: Mechanisms of drug absorption and excretion. Passage of drugs in and out of the central nervous system. Annu Rev Pharmacol Toxicol 2:109128, 1962 Rall DF, Zubrod CG: Mechanisms of drug absorption and excretion. Passage of drugs in and out of the central nervous system. Annu Rev Pharmacol Toxicol 2:109–128, 1962

    • Search Google Scholar
    • Export Citation
  • 43.

    Rapoport SI : Blood-Brain Barrier in Physiology and Medicine. New York: Raven Press, 1976 Rapoport SI: Blood-Brain Barrier in Physiology and Medicine. New York: Raven Press, 1976

    • Search Google Scholar
    • Export Citation
  • 44.

    Recht L, , Torres CO, & Smith TW, et al: Transferrin receptor in normal and neoplastic brain tissue: implications for braintumor immunotherapy. J Neurosurg 72:941945, 1990 Recht L, Torres CO, Smith TW, et al: Transferrin receptor in normal and neoplastic brain tissue: implications for braintumor immunotherapy. J Neurosurg 72:941–945, 1990

    • Search Google Scholar
    • Export Citation
  • 45.

    Riedel CJ, , Muraszko KM, & Youle RF: Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons. Proc Natl Acad Sci USA 87:50515055, 1990 Riedel CJ, Muraszko KM, Youle RF: Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons. Proc Natl Acad Sci USA 87:5051–5055, 1990

    • Search Google Scholar
    • Export Citation
  • 46.

    Ringkjøb R: Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand 44:318322, 1968 Ringkjøb R: Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand 44:318–322, 1968

    • Search Google Scholar
    • Export Citation
  • 47.

    Rostaing-Capaillon O, & Casellas P: Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo. Cancer Res 50:29092916, 1990 Rostaing-Capaillon O, Casellas P: Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo. Cancer Res 50:2909–2916, 1990

    • Search Google Scholar
    • Export Citation
  • 48.

    Rybak SM, & Youle RJ: Clinical use of immunotoxins. Human Cancer Immunol 11:359380, 1991 Rybak SM, Youle RJ: Clinical use of immunotoxins. Human Cancer Immunol 11:359–380, 1991

    • Search Google Scholar
    • Export Citation
  • 49.

    Schmidberger H, , King L, & Lasky L, et al: Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Cancer Res 50:32493256, 1990 Schmidberger H, King L, Lasky L, et al: Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Cancer Res 50:3249–3256, 1990

    • Search Google Scholar
    • Export Citation
  • 50.

    Sendelbeck SL, & Urquhart J: Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion. Brain Res 328:251258, 1985 Sendelbeck SL, Urquhart J: Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion. Brain Res 328:251–258, 1985

    • Search Google Scholar
    • Export Citation
  • 51.

    Shindelman JE, , Ortmeyer AE, & Sussman HH: Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 27:329334, 1981 Shindelman JE, Ortmeyer AE, Sussman HH: Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 27:329–334, 1981

    • Search Google Scholar
    • Export Citation
  • 52.

    Shockley TR, , Lin K, & Sung C, et al: A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52:357366, 1992 Shockley TR, Lin K, Sung C, et al: A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52:357–366, 1992

    • Search Google Scholar
    • Export Citation
  • 53.

    Sung C, , Shockley TR, & Morrison PF, et al: Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 52:377384, 1992 Sung C, Shockley TR, Morrison PF, et al: Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 52:377–384, 1992

    • Search Google Scholar
    • Export Citation
  • 54.

    Sung C, , Wilson D, & Youle RJ: Comparison of protein synthesis inhibition kinetics and cell killing induced by immunotoxins. J Biol Chem 266:1415914162, 1991 Sung C, Wilson D, Youle RJ: Comparison of protein synthesis inhibition kinetics and cell killing induced by immunotoxins. J Biol Chem 266:14159–14162, 1991

    • Search Google Scholar
    • Export Citation
  • 55.

    Sung C, , Youle RJ, & Dedrick RL: Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. Cancer Res 50:73827392, 1990 Sung C, Youle RJ, Dedrick RL: Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. Cancer Res 50:7382–7392, 1990

    • Search Google Scholar
    • Export Citation
  • 56.

    Trowbridge IS, & Domingo DL: Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature 294:171173, 1981 (Letter) Trowbridge IS, Domingo DL: Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature 294:171–173, 1981 (Letter)

    • Search Google Scholar
    • Export Citation
  • 57.

    Trowbridge IS, , Newman RA, & Domingo DL, et al: Transferrin receptors: structure and function. Biochem Pharmacol 33:925932, 1984 Trowbridge IS, Newman RA, Domingo DL, et al: Transferrin receptors: structure and function. Biochem Pharmacol 33:925–932, 1984

    • Search Google Scholar
    • Export Citation
  • 58.

    Uhr J: Immunotoxins: harnessing nature's poisons. J Immunol 133:ix, 1984 Uhr J: Immunotoxins: harnessing nature's poisons. J Immunol 133:i–x, 1984

    • Search Google Scholar
    • Export Citation
  • 59.

    Vitetta E, , Stone M, & Amlot P, et al: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:40524058, 1991 Vitetta E, Stone M, Amlot P, et al: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51: 4052–4058, 1991

    • Search Google Scholar
    • Export Citation
  • 60.

    Walker MD, , Alexander E Jr, & Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333343, 1978 Walker MD, Alexander E Jr, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343, 1978

    • Search Google Scholar
    • Export Citation
  • 61.

    Wallner KE, , Galicich JH, & Krol G, et al: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:14051409, 1989 Wallner KE, Galicich JH, Krol G, et al: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409, 1989

    • Search Google Scholar
    • Export Citation
  • 62.

    Watanabe Y, , Miyazaki H, & Osawa T: Effect of a monoclonal anticarcinoembryonic antigen antibody-ricin A-chain conjugate on human carcinoembryonic antigen-producing tumor cells. J Pharmacobiodyn 7:593603, 1984 Watanabe Y, Miyazaki H, Osawa T: Effect of a monoclonal anticarcinoembryonic antigen antibody-ricin A-chain conjugate on human carcinoembryonic antigen-producing tumor cells. J Pharmacobiodyn 7:593–603, 1984

    • Search Google Scholar
    • Export Citation
  • 63.

    Weiner LM, , O'Dwyer J, & Kitson J, et al: Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chair immunoconjugate. Cancer Res 49:40624067, 1989 Weiner LM, O'Dwyer J, Kitson J, et al: Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chair immunoconjugate. Cancer Res 49:4062–4067, 1989

    • Search Google Scholar
    • Export Citation
  • 64.

    Youle R, & Colombatti M: Immunotoxins: monoclonal antibodies linked to toxic proteins for bone marrow transplantation and cancer therapy, in Roth J (ed): Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. New York: Futura, 1986, pp 173213 Youle R, Colombatti M: Immunotoxins: monoclonal antibodies linked to toxic proteins for bone marrow transplantation and cancer therapy, in Roth J (ed): Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. New York: Futura, 1986, pp 173–213

    • Search Google Scholar
    • Export Citation
  • 65.

    Youle RJ: Mutations in diphtheria toxin to improve immunotoxin selectivity and understand toxin entry into cells. Semin Cell Biol 2:3945, 1991 Youle RJ: Mutations in diphtheria toxin to improve immunotoxin selectivity and understand toxin entry into cells. Semin Cell Biol 2:39–45, 1991

    • Search Google Scholar
    • Export Citation
  • 66.

    Young B, , Oldfield EH, & Markesbery WR, et al: Reoperation for glioblastoma. J Neurosurg 55:917921, 1981 Young B, Oldfield EH, Markesbery WR, et al: Reoperation for glioblastoma. J Neurosurg 55:917–921, 1981

    • Search Google Scholar
    • Export Citation
  • 67.

    Zovickian J, , Johnson VG, & Youle RJ: Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. J Neurosurg 66:850861, 1987 Zovickian J, Johnson VG, Youle RJ: Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. J Neurosurg 66:850–861, 1987

    • Search Google Scholar
    • Export Citation
  • 68.

    Zovickian J, & Youle RJ: Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. J Neurosurg 68:767774, 1988 Zovickian J, Youle RJ: Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. J Neurosurg 68:767–774, 1988

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 436 130 13
Full Text Views 198 9 2
PDF Downloads 89 2 0
EPUB Downloads 0 0 0